US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Add as a preferred source on Google
GAITHERSBURG, Md., March 06, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference and the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium.
| 30th Annual ROTH Conference Presentation Details | ||
| Date: | Tuesday, March 13 | |
| Time: | 7:00pm Eastern Time/4:00pm Pacific Time | |
| Location: | The Ritz Carlton Orange County, Newport Beach, California – Salon 6 | |
| B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) | ||
| Date: | Saturday, March 17 | |
| Time: | 8:30am China Time/7:30pm Eastern Time – Room A | |
| Location: | Intercontinental Hotel, Hangzhou, China | |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including, NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
Email: [email protected]
Ashley Robinson
Managing Director LifeSci Advisors
Phone: 617-535-7742
Email: [email protected]
